- March 15, 2022
- Newsletter
- 617-430-5616
Menu
» Home » Drug Database » Antidepressants » Antidepressants Other » citalopram
ADVERTISEMENT
ADVERTISEMENT
» Home » Drug Database » Antidepressants » Antidepressants Other » citalopram
Brand Name :
Celexa
Synonyms :
Class :
Selective serotonin reuptake inhibitors and Antidepressants
No drug interaction found for citalopram and .
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
when both drugs are combined, there may be increased toxicity of citalopram by QTC interval
may increase the serum concentration of colchicine
may enhance the serum concentrations of active metabolites
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the tachycardic effect of Alpha-/Beta-Agonists
may diminish the serum concentration of Voxelotor
omeprazole: they may enhance the serum concentration of citalopram
acetaminophen/doxylamine/dextromethorphan
may increase the serotonergic effect when combined
lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors
sirolimus: they may enhance the serum concentration of CYP3A4 Inhibitors
may have an increased QTc-prolonging effect when combined with citalopram
budesonide: they may enhance the serum concentration of CYP3A4 Inhibitors
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
alfentanil: they may enhance the serum concentration of CYP3A Inhibitors
budesonide: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cisapride: they may enhance the serum concentration of CYP3A Inhibitors
dapoxetine: they may enhance the serum concentration of CYP3A Inhibitors
eliglustat: they may enhance the serum concentration of CYP3A Inhibitors
fentanyl: they may enhance the serum concentration of CYP3A Inhibitors
lumateperone: they may enhance the serum concentration of CYP3A Inhibitors
mitapivat: they may enhance the serum concentration of CYP3A Inhibitors
naloxegol: they may enhance the serum concentration of CYP3A Inhibitors
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with citalopram
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
It may enhance the toxicity when combined with sufentanil by serotonin levels
It may enhance QTc interval when combined with lithium
May increase the hypoglycemic effect of each other when combined
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, both increase the QTC interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of citalopram
when used together, entrectinib and citalopram both increase the QTc interval
when used together, encorafenib and citalopram both increase the QTc interval
when both drugs are combined, there may be an increase in the QTC interval
it increases the antiplatelet impact of escitalopram
may increase the QTc interval when combined
may enhance the serum concentration
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
they decrease the concentration of lurbinectedin in the serum
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
pimozide: they may enhance the serum concentration of CYP3A4 Inhibitors
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
may have an increased risk of hypoglycemia when combined with citalopram
fexinidazole: they may enhance the serum concentration of CYP3A4 inhibitors
fusidic acid: they may enhance the serum concentration of CYP3A inhibitors
trabectedin: they may diminish the serum concentration of CYP3A Inhibitors
when both drugs are combined, there may be an increased effect of other antiplatelet agents
when both drugs are combined, there may be an increased effect of other antiplatelet agents
when both drugs are combined, there may be an increased effect of other antiplatelet agents
when both drugs are combined, there may be an increased effect of other antiplatelet agents
when both drugs are combined, there may be an increased effect of other antiplatelet agents
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may increase the serum concentration
may increase the serum concentration
bazedoxifene/conjugated estrogens
may increase the serum concentration
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
it may enhance the risk of QTc prolongation when combined with amifampridine
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
when ajmaline is used together with citalopram, the risk or seriousness of QTc prolongation is enhanced
Combining tegafur with citalopram can reduce tegafur’s metabolism
QTc interval is increased both by lenvatinib and citalopram
the effect of citalopram is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
it may increase the effect of other selective serotonin reuptake inhibitors
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
may increase the levels of each other by decreasing the metabolism
May enhance the effects of the other by pharmacodynamic synergism
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
they decrease the concentration of active metabolites of roflumilast in the serum
may increase the serum concentration
may increase the serum concentration of CYP3A4 substrates
azelastine/fluticasone intranasal
may enhance the serum concentration
may increase the serum concentration of abemaciclib
may increase the hyponatremic effect of thiazide and thiazide-like diuretics
CYP3A4 inhibitors increase the concentration of carbamazepine in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
CYP3A4 inhibitors increase the concentration of rivaroxaban
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the serotonergic effect of Serotonin 5-HT1D Receptor Agonists
may increase the serotonergic effect of Serotonin 5-HT1D Receptor Agonists
may increase the serum concentration of Lidocaine
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may increase the levels of serum concentration of pimavanserin
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the levels of serum concentration
synthetic conjugated estrogens, b
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
It may enhance the serum concentration when combined with CYP3A4 Inhibitors
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may enhance the serum concentration of Vitamin D Analogs
SSRIs increase the CNS depressing effect of brexanolone
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
dofetilide: they may enhance the serum concentration of CYP3A Inhibitors
finerenone: they may enhance the serum concentration of CYP3A Inhibitors
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
fusidic acid and betamethasone
may enhance the serum concentration when combined
may enhance the risk of hypoglycemia when combined with Citalopram
may have an increased risk of gastrointestinal bleeding when combined with citalopram
clofazimine: they may enhance the serum concentration of CYP3A inhibitors
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
it increases the antiplatelet effect of fluoxetine
they increase the concentration of glasdegib in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
Adverse drug reactions:
Frequency Defined
>10%
Xerostomia
Increased sweating
Dry mouth
Nausea
Somnolence
Insomnia
1-10%
Dyspepsia
Anorexia
Abdominal pain
Agitation
Impotence
Ejaculation disorder
Rhinitis
Upper respiratory infection
Sinusitis
Dysmenorrhea
Pregnancy warnings:
AU TGA Pregnancy Category: C
US FDA Pregnancy Category: C
Breastfeeding warnings:
crosses into breast milk- known
Pregnancy Categories:
Patient Information Leaflet
Generic Name: Citalopram
Why do we use Citalopram?
Citalopram belongs to the class of Selective serotonin reuptake inhibitors which helps to treat obsessive-compulsive disorder, depression, Major Depressive Disorder, Panic Disorder, Post-traumatic stress disorder, Generalized Anxiety Disorder, and Premenstrual Dysphoric Disorder
ADVERTISEMENT
» Home » Drug Database » Antidepressants » Antidepressants Other » citalopram
Brand Name :
Celexa
Synonyms :
Class :
Selective serotonin reuptake inhibitors and Antidepressants
Dosage Forms & Strengths
Tablet
10mg
20mg
40mg
Oral-solution
10mg/5mL
Dosage Forms & Strengths
Tablet
10mg
20mg
40mg
Oral-solution
10mg/5mL